Source: https://www.patentdocs.org/2011/06/court-report.html
Timestamp: 2019-04-19 11:15:37+00:00

Document:
Novozymes A/S et al. v. Central Trading Enterprises, Inc.
• Plaintiffs: Novozymes A/S; Novozymes North America, Inc.
• Defendant: Central Trading Enterprises, Inc.
Infringement of U.S. Patent Nos. 6,255,084 ("Thermostable Glucoamylase," issued July 3, 2001) and 7,060,468 (same title, issued June 13, 2006) based on CTE's manufacture and sale of its GLUCOAMYL L 706+ and GLUCOAMYL LG20 products. View the complaint here.
Teva Neuroscience, Inc. et al. v. Apotex Inc. et al.
• Plaintiffs: Teva Neuroscience, Inc.; Teva Pharmaceuticals USA, Inc.; Teva Pharmaceutical Industries Ltd.
Infringement of U.S. Patent No. 5,453,446 ("Use of the R-Enantiomers of N-Propargyl 1-Aminoindan Compounds for Treating Parkinson's Disease," issued September 26, 1995) following a Paragraph IV certification as part of Apotex's filing of an ANDA to manufacture a generic version of Teva's Azilect® (rasagiline mesylate, used to treat idiopathic Parkinson's disease). View the complaint here.
Astellas US LLC et al. v. Sagent Pharmaceuticals, Inc. et al.
Infringement of U.S. Patent No. 5,731,296 ("Selective Vasodilation by Continuous Adenosine Infusion," issued March 24, 1998), licensed to Astellas, following a Paragraph IV certification as part of Sagent's filing of an ANDA to manufacture a generic version of Astellas' Adenoscan® product (adenosine injection, used as a diagnostic for myocardial reperfusion injury). View the complaint here.
Depomed, Inc. et al. v. Sun Pharma Global FZE et al.
• Defendants: Sun Pharma Global FZE; Sun Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Inc.
Infringement of U.S. Patent Nos. 6,723,340 ("Optimal Polymer Mixtures for Gastric Retentive Tablets," issued April 20, 2004), 6,635,280 ("Extending the Duration of Drug Release Within the Stomach During the Fed Mode," issued October 21, 2003), 6,488,962 ("Tablet Shapes to Enhance Gastric Retention of Swellable Controlled-Release Oral Dosage Forms, issued December 3, 2002), 6,340,475 ("Extending the Duration of Drug Release Within the Stomach During the Fed Mode," issued January 22, 2002), 7,736,667 ("Shell-and-Core Dosage Form Approaching Zero-Order Drug Release," issued June 15, 2010), 7,780,987 ("Controlled Release Dosage Forms," issued August 24, 2010) following a Paragraph IV certification as part of Sun's filing of an ANDA to manufacture a generic version of Depomed's Glumetza® (metformin hydrochloride extended release tablets, used to improve glycemic control in adults with type 2 diabetes mellitus). View the complaint here.
GlaxoSmithKline LLC v. Roxane Laboratories Inc. et al.
Infringement of U.S. Patent Nos. 5,565,467 ("Androstenone Derivative," issued October 15, 1996), 5,846,976 (same title, issued December 8, 1998), and 5,998,427 ("Androstenones," issued December 7, 1999) following a paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of GSK's Avodart® (dutasteride, used to treat symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate). View the complaint here.
Sanofi-Aventis U.S. LLC et al. v. Sun Pharma Global FZE et al.
• Plaintiffs: Sanofi-Aventis U.S. LLC; Sanofi-Aventis; Debiopharm S.A.
• Defendants: Sun Pharma Global FZE; Sun Pharmaceutical Industries, Inc.; Sun Pharmaceutical Industries Ltd.; Caraco Pharmaceutical Laboratories, Ltd.
Infringement of U.S. Patent Nos. 5,338,874 ("Cis oxalato (trans 1-1,2-cyclohexanediamine) PT(II) Having Optically High Purity," issued August 16, 1994), 5,716,988 ("Pharmaceutically Stable Preparation of Oxaliplatinum," issued February 10, 1998), and 5,959,133 ("Process for the Preparation of Platinum Compounds," issued September 28, 1999) following a paragraph IV certification as part of Sun's filing of an ANDA to manufacture a generic version of plaintiffs' Eloxatin® (oxaliplatin for injection, used to treat colorectal cancer). View the complaint here.

References: v. 
 v. 
 v. 
 v. 
 v. 
 v.